An Open-Label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3.

Trial Profile

An Open-Label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Midostaurin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Mar 2009 Additional lead trial centre/investigator identified as reported by ClinicalTrials.gov, last updated 11 Mar 2009
    • 11 Mar 2009 Additional lead trial centre/investigator identified as reported by ClinicalTrials.gov, last updated 11 Mar 2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top